282 related articles for article (PubMed ID: 16675571)
1. N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors.
Lascombe I; Clairotte A; Fauconnet S; Bernardini S; Wallerand H; Kantelip B; Bittard H
Clin Cancer Res; 2006 May; 12(9):2780-7. PubMed ID: 16675571
[TBL] [Abstract][Full Text] [Related]
2. Expression of classic cadherins type I in urothelial neoplastic progression.
Rieger-Christ KM; Cain JW; Braasch JW; Dugan JM; Silverman ML; Bouyounes B; Libertino JA; Summerhayes IC
Hum Pathol; 2001 Jan; 32(1):18-23. PubMed ID: 11172290
[TBL] [Abstract][Full Text] [Related]
3. Expression of E-cadherin and alpha-, beta-, gamma-catenins in patients with bladder cancer: identification of gamma-catenin as a new prognostic marker of neoplastic progression in T1 superficial urothelial tumors.
Clairotte A; Lascombe I; Fauconnet S; Mauny F; Félix S; Algros MP; Bittard H; Kantelip B
Am J Clin Pathol; 2006 Jan; 125(1):119-26. PubMed ID: 16483000
[TBL] [Abstract][Full Text] [Related]
4. Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression.
Mhawech P; Herrmann F; Coassin M; Guillou L; Iselin CE
Cancer; 2003 Oct; 98(8):1649-57. PubMed ID: 14534881
[TBL] [Abstract][Full Text] [Related]
5. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines.
Wallerand H; Cai Y; Wainberg ZA; Garraway I; Lascombe I; Nicolle G; Thiery JP; Bittard H; Radvanyi F; Reiter RR
Urol Oncol; 2010; 28(2):180-8. PubMed ID: 19070520
[TBL] [Abstract][Full Text] [Related]
6. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
Mahnken A; Kausch I; Feller AC; Krüger S
Oncol Rep; 2005 Oct; 14(4):1065-70. PubMed ID: 16142373
[TBL] [Abstract][Full Text] [Related]
7. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors.
Baumgart E; Cohen MS; Silva Neto B; Jacobs MA; Wotkowicz C; Rieger-Christ KM; Biolo A; Zeheb R; Loda M; Libertino JA; Summerhayes IC
Clin Cancer Res; 2007 Mar; 13(6):1685-94. PubMed ID: 17363521
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder.
Wild PJ; Herr A; Wissmann C; Stoehr R; Rosenthal A; Zaak D; Simon R; Knuechel R; Pilarsky C; Hartmann A
Clin Cancer Res; 2005 Jun; 11(12):4415-29. PubMed ID: 15958626
[TBL] [Abstract][Full Text] [Related]
9. Expression of E-cadherin, P-cadherin and N-cadherin in oral squamous cell carcinoma: correlation with the clinicopathologic features and patient outcome.
Pyo SW; Hashimoto M; Kim YS; Kim CH; Lee SH; Johnson KR; Wheelock MJ; Park JU
J Craniomaxillofac Surg; 2007 Jan; 35(1):1-9. PubMed ID: 17296306
[TBL] [Abstract][Full Text] [Related]
10. E-cadherin mRNA expression analysis in evaluating the natural history of urothelial bladder cell carcinoma: results from a long-term follow-up study.
Cai T; Piazzini M; Nesi G; Taddei I; Sardi I; Detti B; Mondaini N; Dal Canto M; Bartoletti R
Oncol Rep; 2007 Apr; 17(4):925-30. PubMed ID: 17342338
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of EIF-5A2 predicts tumor recurrence and progression in pTa/pT1 urothelial carcinoma of the bladder.
Luo JH; Hua WF; Rao HL; Liao YJ; Kung HF; Zeng YX; Guan XY; Chen W; Xie D
Cancer Sci; 2009 May; 100(5):896-902. PubMed ID: 19298601
[TBL] [Abstract][Full Text] [Related]
12. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors.
Bringuier PP; Umbas R; Schaafsma HE; Karthaus HF; Debruyne FM; Schalken JA
Cancer Res; 1993 Jul; 53(14):3241-5. PubMed ID: 8324734
[TBL] [Abstract][Full Text] [Related]
13. Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage.
Caprodossi S; Lucciarini R; Amantini C; Nabissi M; Canesin G; Ballarini P; Di Spilimbergo A; Cardarelli MA; Servi L; Mammana G; Santoni G
Eur Urol; 2008 Sep; 54(3):612-20. PubMed ID: 17977643
[TBL] [Abstract][Full Text] [Related]
14. Tissue microarray analysis of cytoskeletal actin-associated biomarkers gelsolin and E-cadherin in urothelial carcinoma.
Rao J; Seligson D; Visapaa H; Horvath S; Eeva M; Michel K; Pantuck A; Belldegrun A; Palotie A
Cancer; 2002 Sep; 95(6):1247-57. PubMed ID: 12216092
[TBL] [Abstract][Full Text] [Related]
15. Low E-cadherin expression in bladder cancer at the transcriptional and protein level provides prognostic information.
Popov Z; Gil-Diez de Medina S; Lefrere-Belda MA; Hoznek A; Bastuji-Garin S; Abbou CC; Thiery JP; Radvanyi F; Chopin DK
Br J Cancer; 2000 Jul; 83(2):209-14. PubMed ID: 10901372
[TBL] [Abstract][Full Text] [Related]
16. Expression of Maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis.
Friedrich MG; Toma MI; Petri S; Cheng JC; Hammerer P; Erbersdobler A; Huland H
Eur Urol; 2004 Jun; 45(6):737-43. PubMed ID: 15149745
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of E-cadherin, alpha-, beta-, and gamma-catenin in urothelial cancer of the upper urinary tract.
Kashibuchi K; Tomita K; Schalken JA; Kume H; Yamaguchi T; Muto S; Horie S; Kitamura T
Eur Urol; 2006 May; 49(5):839-45; discussion 845. PubMed ID: 16426728
[TBL] [Abstract][Full Text] [Related]
18. Value of reverse transcription polymerase chain assay in peripheral blood of patients with urothelial cancer.
Okegawa T; Kinjo M; Nutahara K; Higashihara E
J Urol; 2004 Apr; 171(4):1461-6. PubMed ID: 15017198
[TBL] [Abstract][Full Text] [Related]
19. Promoter hypermethylation identifies progression risk in bladder cancer.
Yates DR; Rehman I; Abbod MF; Meuth M; Cross SS; Linkens DA; Hamdy FC; Catto JW
Clin Cancer Res; 2007 Apr; 13(7):2046-53. PubMed ID: 17404085
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin.
Miyata Y; Sagara Y; Kanda S; Hayashi T; Kanetake H
Hum Pathol; 2009 Apr; 40(4):496-504. PubMed ID: 19121849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
